BioCentury Inc.

House Select Committee on Chinese Communist Party taking aim at clinical trials conducted at PLA hospitals and in Xinjiang Uyghur Autonomous Region. Letter to FDA, legislation planned.

How do you launch four products in parallel? @AstellasUS CCO Claus Zieler speaks to @FishburnSimone on The BioCentury Show about converting a global strategy to a local operation, in multiple locations, and what small biopharmas wishing to commercialize products themselves should think about.

You won't want to miss ❗ Greg Verdine, Co-Founder, President & CEO of LifeMine Therapeutics and Professor of Chemistry at Harvard University is joining #BioCenturyGrandRounds to deliver a keynote address: Blowing up the small molecule paradigm. Download the conference brochure to view the full agenda and who you will meet: https://loom.ly/TGB3Mmk Register: https://loom.ly/xUy6IGo

Friday is the last day to save $200 when you register for the 11th China Healthcare Summit at our Early Bird rate! For over a decade, the China Summit has been the destination for biopharma leaders from Asia and the West to network, partner, and debate critical issues facing the industry.   This year, more than ever, it is important we continue this dialogue, and meet again in person. Register for the #BioCenturyChinaSummit and save with Early Bird rates: https://loom.ly/Q57Y6Sg Learn more about the Summit: https://loom.ly/VlKKOYQ #biopharma #biotech #lifesciences #VCs #drugdevelopment

Lead-212’s leading players: Decisions about manufacturing, which could make-or-break the class, are the key differentiators among the drug developers producing their own lead-212

Are you joining the debate at BioCentury Inc. Grand Rounds in Nashville, Sept. 9-11? This event will challenge how you think about drug discovery and translation. ➣ Is there value in new animal models? ➣ Should we blow up the small molecule paradigm? ➣ Are iPSCs poised to reshape cell therapy? ➣ Can researchers deliver new neurology targets and biomarkers? ➣ And much more... ✅ Register by Aug. 2 to qualify for the Advance Rate discount: https://lnkd.in/dJVptkyH I hope to see you there! P.S. Only a few presenting company slots remain. Please send me a DM if interested. #translation #drugdiscovery #celltherapy #stemcells #neurology #BioCenturyGrandRounds

Battle of the alphas: lead-212 vs. actinium-225 in cancer radioligand therapy. The rapid decay of ɑ-emitting radioisotope lead-212 has logistical drawbacks, but its supply could beat actinium-225's on scale.

Academics hold key data and innovations driving the biomedical data revolution. Industry depends on these tools to uncover disease targets and predictive markers. Bridging academic science with industry needs could greatly boost R&D success. At #BioCenturyGrandRounds, The Human Data Revolution Session will explore how to make these data troves fit for purpose: ➤ Methods-for-purpose: Analytical tools that parse signal from noise, without flattening complexity ➤ Data-for-purpose: Go big, go deep, or go long? Speakers in this session include: ➤ Gonçalo Abecasis, Regeneron ➤ Amy Abernethy, former FDA ➤ Daniel Burkhardt, Cellarity ➤ David B. Goldstein, Actio Biosciences, Inc. ➤ Colin Hill, Aitia ➤ Mathai Mammen, M.D., Ph.D., FogPharma ➤ Elizabeth Ann Stringer, NashBio ➤ And more... Download the conference brochure to view the full agenda: https://loom.ly/TGB3Mmk Register: https://loom.ly/xUy6IGo #biomedicaldata #diseasetargets #markers #humandata

How did AstraZeneca turn around its oncology R&D to become a leader in the field? Simone Fishburn talks to Susan Galbraith, AstraZeneca's head of oncology, about how they inculcated a new environment for decision-making. Part 1 of a 2-part Q&A.

Remembering Lisa Burns, biotech’s ‘CEO whisperer’